

Electronic Acknowledgement Receipt

EFS ID:	3167380
Application Number:	10802013
International Application Number:	
Confirmation Number:	4932
Title of Invention:	Novel cyclosporins
First Named Inventor/Applicant Name:	Bruce F. Molino
Correspondence Address:	Michael L. Goldman Nixon Peabody LLP Clinton Square P.O. Box 31051 Rochester NY 14603-1051 US 5852631304 -
Filer:	Georgia Evans
Filer Authorized By:	
Attorney Docket Number:	20011/1331
Receipt Date:	17-APR-2008
Filing Date:	16-MAR-2004
Time Stamp:	14:31:45
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 1270

RAM confirmation Number		9853			
Deposit Account		141138			
Authorized User					
File Listing:					
Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1	Foreign Reference	pat_EP_0484281_B2.PDF	1019201	no	28
			43e1d01f7eef233db4a43eb088bb2d64e282d1e0		
Warnings:					
Information:					
2	NPL Documents	Prelog_Treatment_Psoriatric.PDF	235541	no	5
			2b989ec1ac154391fc3fd6ee649faea08a164b8c		
Warnings:					
Information:					
3	Extension of Time	20080417_Petition_for_Two_Month_Extension_of_Time_2809_1331.pdf	65275	no	1
			3e95168f128469e20498a960d590c2d1b9eaf0f8		
Warnings:					
Information:					
4		20080417_Amendment_-_2809_1331.pdf	373865	yes	93
			ce2009f5143f1a749ae5458ce2d22542a56642ab		
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Amendment Submitted/Entered with Filing of CPA/RCE		1	1	
	Claims		2	91	
	Applicant Arguments/Remarks Made in an Amendment		92	93	
Warnings:					
Information:					
5	Request for Continued Examination (RCE)	20080417_Request_for_Continued_Examination_2809_1331.pdf	90939	no	1
			e8bf79aa98cd7b6eb576842ba7b8c477d0df3de2		
Warnings:					
This is not a USPTO supplied RCE SB30 form.					
Information:					
6	Information Disclosure Statement Letter	20080417_Supplemental_Information_Disclosure_Statement_for_2809_1331.pdf	55616	no	1
			7566a5d889fc1fc086489bac0d6ea543581b31c0		

Warnings:					
Information:					
7	Information Disclosure Statement (IDS) Filed	20080417_PTO_SB_08A_for_Supplemental_IDS_2809_1331.pdf	111774 4dcb25ca4856b2d4865d72860da09722e86a60d	no	2
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
8	NPL Documents	Bandera_Immunomodulants.PDF	1418517 a6322f50a2deb68cef3649eb18c8f4786c16d4c6	no	17
Warnings:					
Information:					
9	NPL Documents	Bartz_Inhibition_of_Human.PDF	479430 79df4290c36c1be7764b0a82cd8c0fc4b0ff2559	no	5
Warnings:					
Information:					
10	NPL Documents	DEB_025_ADIS_Database.PDF	79365 fda3ca2a080b81252b5cbcc0b4de5a9f42fc50e7	no	2
Warnings:					
Information:					
11	NPL Documents	Inoue_Combined_Interferon.PDF	402863 b3db863e0e3863b241313c05b6256a515b59856e	no	6
Warnings:					
Information:					
12	NPL Documents	Merck_Common_Cold.PDF	129765 635be60adb9d12588f45f210a682fe91881e8b89	no	3
Warnings:					
Information:					
13	NPL Documents	Merck_Viral_Infections.PDF	192813 0203ad44dc953ffe5bbd0d8c81f09c45aec08456	no	4
Warnings:					
Information:					
14	NPL Documents	Nakagawa_Specific_Inhibitor.PDF	485338 c93d64ec2b2c2049b91cfe2ab9bb4899bc11664a	no	6
Warnings:					
Information:					

15	NPL Documents	Paeshuyse_Potent_and_Selective.PDF	81002	no	1
			0816d7574d235f416825bc9db772e7d7a9c4bfec		
Warnings:					
Information:					
16	NPL Documents	Rosenwirth_Debio_025.PDF	179821	no	2
			395f00124776e433d52270cfd1023dcd8dca1d83		
Warnings:					
Information:					
17	Rule 130, 131 or 132 Affidavits	20080417_Molino_Supplemental_declaration_2809_1331.pdf	525815	no	3
			6cfd7a041a284d2258fcae4bbb487828b84045bb		
Warnings:					
Information:					
18	Fee Worksheet (PTO-06)	fee-info.pdf	8272	no	2
			b895f209e1a17278ec951e16978595f185b5dbf6		
Warnings:					
Information:					
Total Files Size (in bytes):			5935212		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.